摘要
目的 探讨微小RNA（miR）-129在胃癌组织中的表达及临床意义,并评估其在两种含铂化疗方案治疗晚期胃癌患者的价值.方法 检测52例胃癌患者福马林固定后石蜡包埋（FFPE）肿瘤组织及11例正常胃组织中miR-129的表达水平,并结合临床病理资料进行分析.结果 miR-129在胃癌组织中表达水平显著高于正常胃组织（P ＜0.01）;miR-129的表达水平与既往治疗史比较差异有统计学意义（P＜0.05）.两个疗程后的疗效与晚期胃癌患者总生存时间明显相关,疗效为部分缓解（PR）、稳定（SD）、疾病进展（PD）的患者中位生存时间分别为8.41（5.29～11.52）、10.16（7.19～13.14）和5.10（3.11～7.08）个月.miR-129高表达患者与低表达患者中位生存时间分别为6.27（5.17 ～7.37）、8.74（6.71 ～10.77）个月,差异有统计学意义（P＜0.05）.miR-129高表达胃癌患者死亡风险比（HR）为miR-129低表达胃癌患者的2.77倍[95％可信区间（CI）：1.12～6.87,P＜0.05];SD、PD患者的HR分别为PR患者的0.95（95％CI：0.351 ～2.562,P＞0.05）和6.02倍（95％CI：1.683 ～21.570,P＜0.01）.结论 胃癌组织中miR-129异常表达,其表达水平与晚期胃癌患者预后显著相关.
Objective To explore the microRNA （miR）-129 expression and its clinical significance in advanced gastric cancer,to evaluate the effectiveness of S-1/oxaliplatin vs.doxifluridine/oxaliplatin regimen and to identify miRNAs as potential prognostic biomarkers in patients with advanced gastric cancer.Methods Total RNAs were extracted from normal and gastric tumor formalinfixed,paraffin embedded （FFPE） specimens.miR-129 expression was quantified using real-time quantitative polymerase chain reaction （real-time PCR） analysis.The correlation between the expression levels of miR-129 with clinical characteristics was analyzed by using chi-square test.Overall survival （OS） in patients with clinicopathological characteristics was analyzed using Kaplan-Meier and Log-rank test.The Cox proportional hazards model was performed to estimate Hazard risk （HR） with 95％ confidence interval （CI） of the linking strength between the different clinical characteristics,the expression of miR-129,and death risk.Results The expression levels of miR-129 were significantly up-regulated in gastric tumors compared to normal gastric tissues （P ＜ 0.01）,and were significantly correlated with the previous treatment （P ＜ 0.05）,but not with gender,age,stage,tumor size and histological type by using Chi-square test.After two-course treatment,therapeutic effectiveness was significantly correlated with OS （P ＜ 0.05）,and Kaplan-Meier survival analysis revealed that the median survival time in patients with PR,SD and PD was 8.41 （5.29-11.52）,10.16 （7.19-13.14） and 5.10 （3.11-7.08） months respectively.The up-regulation of the miR-129 expression was closely associated with shorter OS.The median OS in patient with low expression of miR-129 was 8.74 （6.71-10.77） months.In contrast,the median OS was only 6.27 （5.17-7.37）months in patients with the high expression of miR-129 （P ＜ 0.05）.The results of Cox model showed that the HR of patients SD,and PD was 0.95 （95％ CI：0.351-2.562,P ＞0.05） and 6.02 （95％ CI：1.683-21.570,P ＜0.0l） as compared with PR patients.The median survival time in patients with low miR-129expression was significantly prolonged as compared with that in patients with high miR-129 expression [8.74 （6.71-10.77） and 6.27 （5.17-7.37）,respectively].The HR for death risk in stomach carcinoma patients with high miR-129 expression was 2.77 times higher than in those with low miR-129 expression （95％ CI：1.12-6.87,P ＜ 0.05）.Conclusion Abnormal expression of miR-129 has been implicated in gastric cancer,and the expression level of miR-129 was closely associated with prognosis of advanced gastric cancer patients.miR-129 holds great potential as a prognostic biomarker and a valuable indicator of chemotherapy regimen in gastric cancer.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2014年第3期495-498,共4页
Chinese Journal of Experimental Surgery
基金
国家自然科学基金资助项目（81171653）
江苏省自然科学基金资助项目（BK2011246、BK2011247）
常州市社会发展计划基金资助项目（CJ20112020、CZ20110024、CS20102020）
